JP2021523717A - 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 - Google Patents

代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 Download PDF

Info

Publication number
JP2021523717A
JP2021523717A JP2020564104A JP2020564104A JP2021523717A JP 2021523717 A JP2021523717 A JP 2021523717A JP 2020564104 A JP2020564104 A JP 2020564104A JP 2020564104 A JP2020564104 A JP 2020564104A JP 2021523717 A JP2021523717 A JP 2021523717A
Authority
JP
Japan
Prior art keywords
cells
arid5b
cell
expression
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523717A5 (cg-RX-API-DMAC7.html
Inventor
ジェフリー スティーヴン ミラー
ジェフリー スティーヴン ミラー
フランク マーティン チチョッキ
フランク マーティン チチョッキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2021523717A publication Critical patent/JP2021523717A/ja
Publication of JP2021523717A5 publication Critical patent/JP2021523717A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2020564104A 2018-05-14 2019-05-08 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 Pending JP2021523717A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670962P 2018-05-14 2018-05-14
US62/670,962 2018-05-14
PCT/US2019/031296 WO2019221991A1 (en) 2018-05-14 2019-05-08 Manipulating arid5b expression in immune cells to promote metabolism, survival, and function

Publications (2)

Publication Number Publication Date
JP2021523717A true JP2021523717A (ja) 2021-09-09
JP2021523717A5 JP2021523717A5 (cg-RX-API-DMAC7.html) 2022-05-17

Family

ID=68540927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564104A Pending JP2021523717A (ja) 2018-05-14 2019-05-08 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦

Country Status (7)

Country Link
US (1) US12109236B2 (cg-RX-API-DMAC7.html)
EP (1) EP3793574A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021523717A (cg-RX-API-DMAC7.html)
CN (1) CN112888446A (cg-RX-API-DMAC7.html)
AU (1) AU2019269318A1 (cg-RX-API-DMAC7.html)
CA (1) CA3100312A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019221991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7793517B2 (ja) * 2019-11-28 2026-01-05 アムニオティクス・アーベー ソース細胞から決定的造血細胞を生成する方法
CN111733154B (zh) * 2020-04-30 2022-11-04 和也健康科技有限公司 磁场处理的免疫细胞及其用途
KR20230042671A (ko) * 2020-05-28 2023-03-29 바이오마그네틱 솔루션스 엘엘씨 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법
EP4419541A4 (en) * 2021-10-21 2025-12-17 Univ Texas METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
WO2017112877A1 (en) * 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Chimeric antigen receptors and enhancement of anti-tumor activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6448717B1 (en) 2000-07-17 2002-09-10 Micron Technology, Inc. Method and apparatuses for providing uniform electron beams from field emission displays
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
EP3452580B1 (en) 2016-05-02 2023-08-16 Cerus Corporation Compositions and methods for improved nk cell therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
WO2017112877A1 (en) * 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Chimeric antigen receptors and enhancement of anti-tumor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENES & DEVELOPMENT, vol. Vol.31, No.23-24, JPN6023015475, 2017, pages 2343 - 2360, ISSN: 0005041670 *

Also Published As

Publication number Publication date
US20210154232A1 (en) 2021-05-27
AU2019269318A1 (en) 2021-01-07
EP3793574A4 (en) 2022-03-09
EP3793574A1 (en) 2021-03-24
WO2019221991A1 (en) 2019-11-21
CN112888446A (zh) 2021-06-01
CA3100312A1 (en) 2019-11-21
US12109236B2 (en) 2024-10-08

Similar Documents

Publication Publication Date Title
Ruella et al. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Hatae et al. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment
CN112386680B (zh) 在胃肠道移植物抗宿主病的治疗中使用il-22的方法
JP6858128B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP2021119197A (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
JP2022520402A (ja) 免疫療法のための改変ナチュラルキラー(nk)細胞
Lee et al. Tissue resident Foxp3+ regulatory T cells: sentinels and saboteurs in health and disease
Talker et al. Monocyte biology conserved across species: Functional insights from cattle
US20250333764A1 (en) Engineered regulatory t cells
US12109236B2 (en) Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
JP2024520676A (ja) Nr4a3欠損免疫細胞及びその使用
KR20220061148A (ko) 세포 노화 조절 방법 및 조성물
Ellert-Miklaszewska et al. 7aaRGD-a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas
US20250011764A1 (en) In vivo crispr screening system for discovering therapeutic targets in cd8 t cells
TW202600814A (zh) γδT細胞組合物及使用方法
Cunha et al. Infiltration of tumors is regulated by T cell–intrinsic nitric oxide synthesis
US9376663B2 (en) GPR15-mediated homing and uses thereof
CN107073079A (zh) 包括给予PPAR‑γ激动剂的治疗癌症的方法
HK40044945A (en) Manipulating arid5b expression in immune cells to promote metabolism, survival, and function
WO2026063501A1 (en) Method of enhancing anti-tumor response activity of t cell, method for treating tumor, t cell having enhanced anti-tumor response activity, and pharmaceutical composition
Ellert-Miklaszewska et al. Integrin blocking peptide reverses immunosuppression in experimental gliomas and improves anti-PD-1 therapy outcome
US20250381273A1 (en) Augmenting Mitochondria in Immune Cells for Improved Cancer Immunotherapy
Herek et al. Using Murine Models to Investigate Tumor–Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma
US20230338423A1 (en) Targetable immune checkpoint for immunotherapy
WO2023237754A2 (en) Cyclosporin h and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231109